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Abstract
Myocyte enhancer factor 2 protein (Mef2) is an evolutionarily conserved activator of transcription that is critical to induce
and control complex processes in myogenesis and neurogenesis in vertebrates and insects, and osteogenesis in vertebrates.
In Drosophila, Mef2 null mutants are unable to produce differentiated muscle cells, and in vertebrates, Mef2 mutants are
embryonic lethal. Schistosome worms are responsible for over 200 million cases of schistosomiasis globally, but little is
known about early development of schistosome parasites after infecting a vertebrate host. Understanding basic
schistosome development could be crucial to delineating potential drug targets. Here, we identify and characterize Mef2
from the schistosome worm Schistosoma mansoni (SmMef2). We initially identified SmMef2 as a homolog to the yeast Mef2
homolog, Resistance to Lethality of MKK1P386 overexpression (Rlm1), and we show that SmMef2 is homologous to
conserved Mef2 family proteins. Using a genetics approach, we demonstrate that SmMef2 is a transactivator that can induce
transcription of four separate heterologous reporter genes by yeast one-hybrid analysis. We also show that Mef2 is
expressed during several stages of schistosome development by quantitative PCR and that it can bind to conserved Mef2
DNA consensus binding sequences.
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Introduction
Schistosomiasis is a parasitic disease infecting over 200 million
people worldwide with an at risk population of over 750 million
[1].The disease is caused by blood fluke worms of the genus
Schistosoma, primarily by the species S. mansoni, S. haematobium, and
S. japonicum. Ninety-three percent of worldwide cases of schisto-
somiasis (192 million) occur in sub-Saharan Africa, with the
highest prevalence of disease occurring in school aged children,
adolescents, and young adults, where morbidity is causative of a
variety of symptoms ranging from impaired physical growth to
more than 280,000 deaths per year [2,3,4]. Due to the primary use
of a single drug for treatment, praziquantel, concerns have arisen
regarding the possible development of drug resistance, for which
some reports suggest may be selected for in a laboratory setting
[5]. Because of the profound global impact and the implications of
schistosome caused disease, a complete understanding of the
biology of these organisms is of importance to the research and
medical community.
Schistosomes have a complex parasitic life cycle requiring
molluscan and mammalian hosts and an intricate process of
morphological and functional changes. Free-swimming cercariae
infect the mammalian host via direct penetration of the skin. Upon
host skin invasion, the small 90–215 micrometer long schistosom-
ulum, develops a digestive tract, exchanges its glycocalyx for a
tegument and must grow into a 7–20 millimeter long, muscular
adult worm that is uniquely adapted to its host [6,7,8,9,10,11,12].
Following migration to the venules of the hepatic portal system,
male and female worms pair and produce eggs, which are excreted
from the host. Eggs hatch into miracidia, another morphologically
distinct free-swimming stage that will infect the molluscan host.
Within the snail, sporocysts develop and produce cercariae, which
exit to restart the life cycle. Recent advancements have been made
in schistosome research, including RNAi gene silencing studies
[13,14], microarray analyses [15,16], proteomic analyses [17,18],
laser micro-dissection microscopy of tissues [19], and cell-specific
labeling techniques allowing for in-depth tissue visualization [20].
While promising, there is still little known about the function and
expression of genes within the schistosome parasite throughout its
complex life cycle.
Myocyte enhancer factor (Mef2) proteins are members of the
evolutionarily conserved MADS-box family, named after the four
initially discovered members (Mini Chromosome Maintenance 1,
AGAMOUS, Deficiens, and Serum Response Factor), found in
yeast, Arabidopsis thaliana, Antirrhinum majus, and humans, respec-
tively [21,22,23,24]. The function and expression of Mef2 proteins
have been investigated in many organisms, where they function as
transcription factors that regulate cellular differentiation, morpho-
genesis, proliferation, T-cell selection, and survival [25,26,27].
Mef2 proteins also have a conserved Mef2 protein domain, which
functions with the MADS domain in protein dimerization, DNA
binding, and co-factor interactions; these domains are coupled
with a highly variable, usually C-terminal domain, that functions
in transcriptional activation [26,28,29]. Mef2 proteins bind as
www.plosntds.org 1 January 2012 | Volume 6 | Issue 1 | e1443both homo- and heterodimers to a ten base pair Mef2 consensus
sequence CTAWWWWTAG that is evolutionarily conserved
across multiple species, although some variations to this consensus
have been observed [30,31,32,33].
The single Mef2 gene in Drosophila (D-Mef2) is perhaps the most
studied Mef2 homolog [28], and is required for embryonic
myogenesis [34]. Knockout studies have shown that the loss of D-
Mef2 results in a complete loss of all muscle tissues [35] and loss of
differentiation in all muscle cell lineages: somatic, cardiac, and
visceral [36]. Chromatin immunoprecipitation (ChIP) and DNA
microarrays have been used to elicit over 200 directly targeted
genes in Drosophila and more than 650 regions in the genome
bound by the activator [36,37]. One such target, Actin57B, is
directly regulated by D-Mef2 for differential expression in cardiac,
skeletal, and muscle cell lineages, where it binds to the target
consensus sequence CTATTTTTAG contained in the Actin57B
promoter [38].
The vertebrate Mef2 family has four alternate spliceforms,
Mef2A-D, characterized by highly varied C terminal activation
domains [26] and overlapping, yet distinct patterns of expression
[28]. In mammals, Mef2 requires interaction with other myogenic
basic Helix Loop Helix transcriptional activators to direct
myogenic differentiation [39]. The four homologs play a
significant role in vertebrate heart development, where they act
as regulators of other important cardiac transcription factors
[28,40]. In addition to its role in myogenesis, vertebrate Mef2 acts
as a regulator of neural crest and craniofacial development in both
zebrafish [41] and mammals [42], and aids in activation of bone
development [43], neuronal differentiation [44,45], muscle
regeneration [46], and T-Cell development [28].
Mef2 proteins have conserved DNA binding sites. The
vertebrate Mef2A, -C, and –D have similar DNA binding ability,
although Mef2B exhibits a reduced binding efficacy [26]. Mef2A
and Mef2D bind the most common Mef2 binding consensus
sequence, CTAAAAATAG [33,47]. The Mef2 homolog Rlm1,
from the budding yeast, Saccharomyces cerevisiae, also binds this
consensus sequence and can heterodimerize with mammalian
Mef2A. Rlm1 functions in the mitogen activated protein kinase
pathway as an important mediator in cell wall biosynthesis [48].
Recently, a Mef2 homolog in the liverwort plant species Marchantia
polymorpha (M. polymorpha) was shown to play a role in
gametophytic generation with affinity as a homodimer for the
sequences CTATTTTTAG and CTATATATAG [49], showing
the evolutionary conservation of Mef2 proteins and Mef2 binding
properties.
This evidence suggests that Mef2 is a pivotal and highly
conserved transcriptional activator, making it a prime target of
interest in the functional genetics of S. mansoni. Here, we identify
and characterize the Schistosoma mansoni Mef2 (SmMef2). We
demonstrate that it is a functional transcriptional activator, that it
is expressed during different stages of schistosome development,
and that it recognizes Mef2 specific target sequences. Finally, we




The protein sequence of the yeast Mef2 homolog Rlm1 was used
for a Basic Local Alignment Tool for proteins (BLASTp) analysis
against the S. mansoni genome databases GeneDB [50] and
SchistoDB [51]. Identified sequences were then queried using
Washington University protein Blast (WU-BLASTp) against the S.
cerevisiae and H. sapiens genomes to compare MADS-box and Mef2
regions of homology. BLASTp analysis was done using the
identified Mef2 homolog in S. mansoni against all genomes using
NCBI BLAST (http://blast.ncbi.nlm.nih.gov) to identify other
homologs across a variety of species. Identified protein sequences
were downloaded and compared to S. mansoni Mef2 utilizing
ClustalW2 (http://www.ebi.ac.uk/Tools/msa/clustalw2/) [52,53].
The phylogram phylogenetic tree was drawn from a ClustalW-
generated multiple sequence alignment of Mef2 homologs using the
neighbor-joining method, and a Gonnet protein weight matrix with
the gap open set at 10, the gap extension set at 0.2 and the gap
distances set at 5.
RNA Purification
Total RNA was purified from six-week old adult worms, four-
hour schistosomula, cercariae, and sporocysts using Trizol
Reagent purification (Invitrogen, Carlsbad, CA) and Purelink
columns (Invitrogen, Carlsbad, CA). RNA was quantitated using a
NANODROP 8000 spectrophotometer (Thermo Scientific, Wal-
tham, MA) and gel analysis and RNA quality was assessed by
visualization on a 2% agarose gel.
Sample Preparation
Snails containing the Puerto Rican strain of Schistosoma mansoni
originated from stocks maintained by the NIAID Schistosome
Resource Center at the Biomedical Resource Institute (Rockville,
MD). Transformation of cercariae and culturing of schistosomula
were performed as previously described [54,55].
Molecular Cloning
DNA Primers using the InFusion Cloning System (Clontech,
Mountainview, CA) were designed based on the identified
Smp_129430 (SmMef2) spliced gene sequence and the pGBKT7
vector (Clontech, Mountainview, CA) following manufacturer’s
recommendations. Primers were ordered from Integrated DNA
Technologies (IDT, Coralville, IA). Forward primer oAT007 (59-
GAA TTC CCG GGG ATC CGT CGA CTT ATG GGT CGC
AAA AAA ATA CTC ATC AAG AAG-39) and reverse primer
oAT008 (59-ATG CGG CCG CTG CAG GTC GAC TCA AAG
GTG GCG CAC ACG TTT AAG AGG GTT-39) were used to
clone SmMef2 by the one-step RT-PCR SuperScriptIII/Plati-
Author Summary
Schistosome parasites infect more than 200 million people
worldwide and cause human schistosomiasis. Free-swim-
ming schistosome larvae are highly mobile and invade and
penetrate the host’s skin to perpetuate their lifecycle in
their human host, growing from 90–215 micrometers in
length as a schistosomulum to a 7–20 millimeter long
adult worm. Few molecular pathways have been identified
in schistosome worms that are important for parasite early
development. The myocyte enhancer factor protein 2 is a
major regulator of muscle and nerve development in
mammals and insects and is highly conserved from bread
yeast to vertebrates. Here we identify and characterize the
Mef2 activator from parasitic schistosome worms, the first
described in any parasitic worm, and delineation of its
function may be important to further understanding the
basic biology of schistosome early development. Addi-
tionally, since schistosomes developed early evolutionarily,
an investigation of schistosome Mef2 regulatory mecha-
nisms could lead to a greater understanding of the
development of early muscle and neurogenic develop-
ment in animals.
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RNA from sporocyst, cercariae, and adult worms. The cDNA
product was subcloned into vector pGBKT7 (Clontech, Moun-
tainview, CA) at the Sal I site and this plasmid was used to
transform chemically competent One Shot TOP10 cells (Invitro-
gen, Carlsbad, CA). Colonies were selected and grown in LB
containing kanamycin liquid media. Plasmid DNA was purified
using the Nucleospin Plasmid miniprep kit (Clontech, Mountain-
view, CA) and verified by restriction analysis and DNA sequencing
to make plasmid pEJ1108.
SmMef2 from plasmid pEJ1108 was amplified by PCR and
subcloned between Not I and Sal I sites of the expression vector
pMAL-c5x (New England Biolabs, Ipswitch, MA) using InFusion
(Clontech, Mountainview, CA) with forward primer oAT019 (59-
TCC ATG GGC GGC CGC ATG GGT CGC AAA AAA ATA
CTC ATC AAG) and reverse primer oAT020 (59-TTC GGA
TCC GTC GAC TCA AAG GTG GCG CAC ACG TTT AAG
AGG) to make plasmid pEJ1114. The product was analyzed by
restriction analysis and sequenced.
Modified Yeast 1-Hybrid System
Plasmid pEJ1108 was used to transform yeast strain AH109
(ordered from Clontech, Mountainview, CA; genotype MATa,
trp1-901, leu2-3, 112, ura3-52, his3-200, gal4D, gal80D, LYS2::GA-
L1UAS-GAL1TATA-HIS3, GAL2UASGAL2TATA-ADE2,URA3::ME-
L1UAS-MEL1TATA-LacZ, MEL1) and grown on SD -Trp plates.
Transcriptional activity was tested using four different reporter
genes present in the AH109 strain. Each reporter gene (HIS3,
ADE2, lacZ, MEL1; encoding histidine 3, adenine 2, beta-
galactosidase, and alpha galactosidase, respectively) is under
control of a Galactose 4 protein (Gal4) dependent promoter and
grown on selective synthetic media (SD). AH109 transformed with
the pGBKT7 vector alone served as a negative control, and
positive controls used AH109 transformed with pEJ780, a
pGBKT7-based plasmid containing the full Galactose 4 transcript
(GAL4). Expression of Histidine and Adenine auxotrophy was also
tested by spot test analysis using four, 10-fold serial dilutions of
liquid synthetic media without the amino acid tryptophan (SD –
Trp), then grown on selective media missing either adenine,
histidine or tryptophan (SD –Ade, SD –His, SD –Trp,
respectively). O.D.600 values of the positive control, negative
control, and experimental cultures were matched before plating
using the Nanodrop 8000. Growth was indicative of a positive
result. Expression of MEL1 was tested by an a-galactosidase assay
on SD -Trp where yeast cells were screened for blue color.
Expression of lacZ was tested by a b-galactosidase assay and
screened for blue color.
Reverse Transcription and Quantitative PCR
RNA reverse transcription reactions were carried out using
SuperScript III RT, RNAse OUT, and oligo (dT)12–18 (Invitrogen,
Carlsbad, CA) using 1 mg of total RNA extracted from sporocysts,
cercariae, schistosomula, and adult worms, as per manufacturer’s
recommendations. The reaction was carried out for one hour at
50uC, and treated with 10 U RNase H (New England Biolabs,
Ipswitch, MA) and placed at 37uC for 20 minutes to remove any
hybridized mRNA.
Quantitative Polymerase Chain Reaction (quantitative PCR)
primers were designed using primer 3 software [56] (Table S1).
Primers were checked for specificity using NCBI Primer-BLAST
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and for het-
ero- and homo-dimers and hairpin structures using Oligo Analyzer
(http://www.idtdna.com/analyzer/applications/oligoanalyzer/).
Quantitative PCR was performed using SYBR Green master mix
on a StepOnePlus Real-Time PCR system with StepOne Version
2.0 software (Applied Biosystems, Carlsbad, CA), using 2 mL of the
Reverse Transcriptase (RT) reactions described above. The
following quantitative PCR conditions were used: 95uC for
10 minutes, 40 cycles of 95uC for 15 seconds and 60uC for
1 minute, followed by melt curve analyses. Replicates were
manually screened, and those containing significant multiple
melting peaks or bad passive reference signals were removed from
analysis. Threshold cycle values and standard curve parameters
were determined as described above. Cycle threshold (CT) values
of Mef2 and potential downstream targets were evaluated by
2
2DDCT methods using cyclophilin as a reference gene with
sporocysts as an endogenous control. CT values for cyclophilin
were consistent across all stages tested. Bar graphs were generated
using StepOne software (Applied Biosystems). Error bars represent
standard error [57].
Protein Expression and Purification
Vectors pEJ1114 and pMAL-c5x (New England Biolabs,
Ipswich, MA) that express either a Maltose binding protein fused
to SmMef2 (MBP-SmMef2) or Maltose Binding Protein (MBP)
alone were used to transform BL21 DE3 cells (Invitrogen,
Carlsbad, CA). Cultures were shaken at 37uC to an O.D.600 of
0.9 and protein expression was induced with IPTG at a final
concentration of 2 mM. The culture was shaken for 19.5 hr at
20uC. Cell extracts were prepared as outlined in the pMAL
Protein Fusion and Purification System manual (New England
Biolabs, Ipswitch, MA). Briefly, cells were resuspended in column
buffer with PMSF and Halt protease inhibitor cocktail (Thermo
Scientific, Waltham, MA), lysed with lysozyme and pulse
sonification, and cleared by centrifugation at 12,5006g for
30 min. Protein was purified by diluting cell extract 1:6 and
running through a gravity column consisting of 10 mL Amylose
High Flow Resin (New England Biolabs, Ipswitch, MA). Protein
was eluted with maltose and then transferred to storage buffer by
utilizing 100,000 MWCO Amicon Ultra 2 ml centrifugal filters.
Total protein concentration was quantitated by Bradford assay.
Electrophoretic Mobility Shift Analysis
DNA binding oligonucleotide sequences were designed based
on the Actin57B promoter region from Drosophila melanogaster,
specifically, the region from 2218 bp to 2188 bp of the
translation start codon (59-GCTGAAGGAT{ctatttttag}GCG-
GATCGGC-39), which contains a Drosophila Mef2 binding site
(internal brackets) [38]. Three double-stranded oligonucleotide
pairs AT11, AT12, and AT13 (labeled as F for forward and R for
reverse complement) were designed that make three different
versions of the Mef2 binding consensus. Oligonucleotide oAT11F
(59-GCTGAAGGAT{ctatttttag}GCGGATCGGC-39), the for-
ward sequence for the double stranded oligo-pair AT11, and
reverse complement oligonucleotide oAT11R (59-
GCCGATCCGCCTAAAAATAGATCCTTCAGC-39) were
used. For subsequent oligos, the internal Mef2 site was modified
to test other Mef2 binding sites. Double-stranded oligonucleotide
(ds-oligo) AT12 contains one of the most common consensus
binding sequences [47,58], made up of the forward and reverse
complement oligonucleotides oAT12F (59-GCTGAAGGAT{c-
taaaaatag}GCGGATCGGC-39) and oligonucleotide oAT12R
(59-GCCGATCCGCCTATTTTTAGATCCTTCAGC-39). Ds-
oligo AT13 contains an M. polymorpha Mef2 binding site, generated
with oligonucleotide oAT13F (59-GCTGAAGGAT{ctatata-
tag}GCGGATCGGC-39) and oAT13R (59- GCCGATCCGCC-
TATATATAGATCCTTCAGC-39) [49]. Ds-oligo AT14 con-
tains the DNA binding site for the S. cerevisiae gene NDT80 as a
Mef2 Transcriptional Activator in Schistosomes
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caaaat}GCGGATCGGC-39) and oAT14R (59- GCCGATCCG-
CATTTTGTGACATCCTTCAGC-39) [59,60]. For all double-
stranded ‘‘hot’’ oligonucleotides, the forward oligonucleotides
were designed with a 59 biotin label, while ‘‘cold’’ double-stranded
oligonucleotides were designed with no biotin label; all oligonu-
cleotides were ordered from Integrated DNA Technologies (IDT,
Coralville, IA). Oligonucleotides were annealed by mixing
equimolar amounts of forward and reverse oligonucleotides in
.05 M NaCl, .01 M Tris pH8.0, and 1 mM EDTA. The
oligonucleotides were boiled at 95uC for 10 min, and then cooled
1uC per 60 sec down to 23uC on a Multigene Thermal Cycler
(Labnet Technologies, Edison, NJ).
Electrophoretic Mobility Shift Assay (EMSA) reactions were
performed using the LightShift Chemiluminescent EMSA kit
(Thermo Scientific, Waltham, MA) as described by the manufac-
turer. Briefly, binding reactions contained 180 fmol hot dsDNA,
36 pmol (2006) cold dsDNA (where applicable), 1.4 mgo f
Amylose-purified protein extract (MBP-SmMef2 or MBP), and
16supplied binding buffer, 2.5% glycerol, 5 mM MgCl2, 50 ng/
mL Poly (dI-dC) Inhibitor DNA, and .05% NP-40. Binding
reactions were prepared on ice and placed at room temperature
for 20 min. Reactions were mixed with supplied 56 loading
buffer, and loaded onto a prerun 10 cm610 cm 5% polyacryl-
amide/0.56TBE native gel, and run in 0.56TBE for 70 min at a
constant voltage of 150V. The gel was placed in a blotting
apparatus with a Biodyne B Pre-Cut Modified Nylon Membrane
(size 0.45 mm, Thermo Scientific, Waltham, MA) and transferred
in 0.56 TBE at constant current of 380 mA for 1 hr. Following
transfer, the membrane was crosslinked on a CL-1000 Ultra Violet
crosslinker (UVP, Upland, CA) on automatic settings for 120 mJ/
cm
2. The membrane was developed according to kit protocol, and
visualized with a Charged Coupled Device (CCD) camera set to
an exposure time of 1–2 min.
Downstream Targets of SmMef2
Potential downstream targets of SmMef2 were screened for
Mef2 binding sites within 5000 bp upstream of the expected
translation start codon. Fifty-six S. mansoni genes were screened
and their upstream sequences were obtained from GeneDB [50].
Putative targets were selected for screening based on suspected
gene function or high levels of homology as revealed by BLASTp
analysis against known Mef2 targets in D. melanogaster [36]. Two
types of binding sites were used for screening; strong consensus
binding sites were defined by the sequence CTAWWWWTAG,
the Mef2 consensus sequence [30,32,33], while weak consensus
binding sites were defined by either CTTWWWWTAG or
CTAWWWWTAA. These sites differ from the common consen-
sus by a single nucleotide in either the third or the last base pair
position. The two ‘‘weak’’ sequences were selected based on a
screening of over 200 Mef2 binding sites, which determined these
two sequences to be the next most frequently occurring binding
sites for Mef2 after the consensus sequence [33]. Binding
sequences and distance upstream of the translation start codon
were noted.
Results and Discussion
Schistosome Parasites Have a Mef2-Like Protein
BLASTp analysis with the yeast Mef2 homolog Rlm1 against
the Schistosoma mansoni genome database identified a putative
myocyte enhancer factor 2 (Smp_129430), which contains
conserved MADS-box and Mef2 domains (Figure S1). A WU-
BLASTp with the putative SmMef2 against the S. cerevisiae yeast
genome showed that the schistosome Mef2 and the yeast Mef2
homolog, Rlm1 are 49% identical and 68% similar across 88
amino acids at the N-terminus, which encodes the MADS Box and
Mef2 domains of putative SmMef2 and Rlm1 (Figure S1A).
BLASTP against the human Mef2A protein showed greater
similarity (Figure S1B). We observed that putative SmMef2 and
human Mef2A, Mef2B, Mef2C and Mef2D proteins are 78–80%
identical and 90% similar across amino acids 1–88 at the N-
Figure 1. The SmMef2 expressed sequence is different from the
published sequence, Smp_129430. The SmMef2 is 2193 nucleo-
tides and encodes for a 731 amino acid protein. It differs from the
currently published sequence the following ways: 1). A G to A transition
occurs at nucleotide 66. This does not affect the amino acid sequence
2). A sequence from nucleotides 1596–1811 is recognized as an intron
in the database, but this sequence is included in the functional coding
sequence, and 3). There is a ten base pair deletion of nucleotides
aacaataat in SmMef2 after nucleotide 1908.
doi:10.1371/journal.pntd.0001443.g001
Figure 2. A graphical depiction of the modified yeast 1-hybrid
system. The Gal4 DBD alone cannot activate reporter genes activity
without an activation domain (A), while the complete Gal4 transcript
will induce reporter activity (B). A fusion protein of Mef2 and the Gal4-
DBD can activate the reporter if Mef2 is a transcriptional activator (C).
doi:10.1371/journal.pntd.0001443.g002
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homology between other Mef2 homologs, where the Mef2 and
MADS-box domains, particularly the MADS-box, are highly
conserved across species [26,28]. When the remaining C-terminus
(amino acids 89–661) of putative SmMef2 was used to search for
homologs by BLASTp in NCBI, excluding putative SmMef2, we
found no protein, nor protein domains with any significant
homology. Although the sequence similarity of the DNA binding
domains of putative SmMef2 and human Mef2 proteins A-D are
highly conserved, the lack of conservation among the activation
domain of SmMef2 is not unsubstantiated as the activation
domain of Mef2 proteins characteristically displays a high degree
of variation, even across homologs within the same species [26,33].
Schistosome Mef2 Is a Transcriptional Activator
To test whether putative SmMef2 is actively expressed, we
extracted RNA from sporocysts, cercariae, and adult worms.
Using a 1:1:1 mixture of RNA from these three developmental
stages for reverse transcriptase PCR (RNA from mixed develop-
mental stages permits amplification in fewer reactions when the
expression profile of a gene is unknown), we cloned a 2,193 base
pair sequence encoding 731 amino acids. The cloned sequence is
67 amino acids larger than predicted in the schistosome database
for the putative Mef2 (Smp_129430). The extra 201 nucleotides
are located in predicted intron 4. There is also a nine-nucleotide
deletion AACAATAAT after nucleotide 1908 of SmMef2
(Figure 1). The corresponding nucleotide and protein sequences
are found in Figure S2. The BLASTp analysis described above
was repeated with the sequenced version of putative SmMef2 with
similar results, which will be referred to as SmMef2, to distinguish
it from sequence Smp_129430. The SmMef2 DNA sequence has
been submitted to the Genbank database under accession number
JN900476.
Mef2 proteins are proposed to have arisen out of a duplication
of the ancestral MADS box domain before the divergence of
plants and animals [61]. In plants, the Mef2-like sequences are
characterized as type II MADS box proteins. To further
characterize SmMef2 relative to other Mef2 proteins, we
constructed a Mef2 phylogenetic tree using ClustalW that includes
sequences from yeast, plants, amphibians, insects, and humans
(Figure S3). The phylogenetic tree demonstrates that SmMef2 is
linked to other Mef2 proteins. We find it intriguing that SmMef2 is
classified within the same lineage as mammalian Mef2B,
suggesting that it might be a Mef2B protein, although at this
point we are not convinced there are enough data to support that
argument. In concurrence with other studies, this phylogenetic
Figure 3. Selection and screening to test ability of SmMef2 to induce reporter genes. Serial dilution spot tests are displayed on –adenine
or –histidine nutritional marker plates to test whether SmMef2 can induce the genes encoding adenine or histidine biosynthesis (A and B,
respectively). Cells are diluted from right (undiluted) to left in 10 fold increments. Alpha galactosidase assay to test whether SmMef2 can induce the
MEL1 reporter gene (C), where blue color indicates reporter gene activation. The negative control is white. To control for growth alone, cell are grown
on media without tryptophan, which selects for the presence of the pGBKT7 plasmid (D).
doi:10.1371/journal.pntd.0001443.g003
Mef2 Transcriptional Activator in Schistosomes
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mammals [62].
Many Mef2 proteins encode for activators of transcription. If
SmMef2 is a Mef2 protein, then it should potentially be able to
function as a transcriptional activator (TA). To test whether
SmMef2 can function as a TA, we took a yeast 1-hybrid genetics
approach, utilizing the yeast expression plasmid pGBKT7
(Clontech, Mountainview, CA) and yeast strain AH109 (Clontech,
Mountainview, CA). A fusion protein was generated combining
the DNA binding domain of Gal4 (Gal4-DBD), from the
expression plasmid pGBKT7, with the full-length SmMef2. The
AH109 strain used for the 1-hybrid analysis contains yeast GAL1
and GAL2 promoters that controls expression of 4 different
reporter genes, Histidine 3 (HIS3), Adenine 2 (ADE2), beta
galactosidase (lacZ), and alpha galactosidase (MEL1). The Gal4-
DBD alone cannot activate the reporter genes and was used as a
negative control (Figure 2A), whereas the complete Gal4 protein
with it own activation domain can activate the reporter genes and
was used as a positive control (Figure 2B). If SmMef2 is a TA, then
when fused to the Gal4 DBD, it will drive transcription by
utilization of the transactivation domain from SmMef2 (Figure 2C).
To test the levels of reporter activity for ADE2 and HIS3 reporter
genes, we performed standard spot tests at comparable dilutions
on test plates with nutritional markers. All cells were grown to log
phase, then diluted to equal cell counts measured to within 0.01
optical density 600 nm (OD600). These were then serially diluted
and grown for 3 days at 30uC. We found that SmMef2 displayed
transcriptional activity in all reporters tested (Figure 3). Serial
dilutions of SmMef2 on SD -Ade and SD -His plates grew
exceptionally well and did not show a reduction in spot size until
10
4-fold dilution, whereas the positive control had a reduction of
growth at a dilution factor of 10
2 (Figure 3A, 3B). The negative
control (Gal4-DBD alone) did not elicit auxotrophy for adenine or
histidine (Figure 3A, 3B). Gal4 is a strong transcriptional activator
in yeast, but we observed that cells expressing the positive control
(full length Gal4 protein) did not grow as well as cells expressing
Mef2 on SD –Ade or SD –His plates [63,64]. This is not surprising
as there is sufficient evidence suggesting that one transcriptional
Figure 4. EMSA Analysis of SmMef2 DNA binding. Double stranded oligonucleotides with Mef2 consensus sequences were designed to test
SmMef2 binding requirements (A). AT14 is the negative control probe (A). An MBP-SmMef2 fusion protein was purified and tested for its ability to
bind double-stranded labeled probes (oligo-pair AT12 and oligo-pair AT13) containing different Mef2 consensus sequences (B and C, respectively).
Purified MBP alone does not bind the DNA probes (B and C Lanes 2), while the MBP-SmMef2 fusion protein binds the probes (B and C, Lanes 3).
Unlabeled oligonucleotide pairs AT11, AT12 and AT13 compete for binding against the labeled reporters (B and C, Lanes 4–6), while nonspecific AT14
does not compete (A and B Lane 7).
doi:10.1371/journal.pntd.0001443.g004
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been reported when using overexpression of Gal4, where the
activator is so strong that it deleteriously affects general
transcription, resulting in reduced growth rate [65]. To directly
test whether slower growth is due to a reduced ability of the
positive control to activate the reporter genes relative to SmMef2,
or whether it is a reduction in growth rate due to overexpression of
the full length Gal4 protein, we tested growth on synthetic media
without tryptophan. The plasmid, pGBKT7 carries a gene that
encodes for tryptophan auxotropy, and was used to clone the
Gal4-DBD/SmMef2 fusion protein and the full length Gal4
protein. Growth on synthetic media without tryptophan (SD –Trp)
does not select for reporter activity but selects for the presence of
the pGBKT7 plasmid; therefore, all cells should grow equally well.
On media without tryptophan, the positive control expressing full
length Gal4 protein grows slower than either Mef2 or the negative
control, which has the plasmid expressing the Gal4-DBD alone
(Figure 3D). The growth on SD –Trp correlates with the growth
rate seen on SD –Ade and SD –His, and corroborates that the
slower growth of the positive control is not due to an inability to
activate the reporter genes.
SmMef2 was also tested for positive transcriptional activity
using an alpha galactosidase assay. In this screen, cells expressing
the MEL1 reporter gene turn blue in the presence of X-alpha-gal
(Clontech, Mountainview, CA), whereas colonies not expressing
the MEL1 reporter will remain white. Twenty-six transformants
were picked, patched, and screened for reporter activity. All 26
colonies tested were blue (Figure 3C). The positive control was
blue and the negative control was white, as expected (Figure 3C).
Similar results were also observed when SmMef2 was tested using
the beta galactosidase assay (data not shown). These data
demonstrate that SmMef2 is a functional activator. The Gal4
system is a common method for testing transcriptional activity in
eukaryotes via heterologous in vivo expression in yeast [64]. Our
demonstration of this approach using a schistosome genes suggests
that this approach could be a viable strategy to elucidate functional
TAs in S. mansoni, as described previously in budding yeast [66].
SmMef2 Binds Conserved Mef2 Consensus Sequences
Mef2 proteins bind DNA directly to regulate diverse develop-
mental programs. Mef2 proteins recognize the DNA consensus
CTAWWWWTAG and bind either as a homo or heterodimer
[28,31,67,68]. We proposed that if SmMef2 is a Mef2 protein, that
it should be able to recognize a version of the Mef2 DNA
consensus. To address binding capabilities of the SmMef2, we
made a protein hybrid of SmMef2 that is N-terminally fused to the
maltose binding protein (MBP-SmMef2). The MBP-SmMef2
protein hybrid was expressed and purified from bacteria and
tested by electrophoretic mobility shift assay (EMSA) to determine
whether it could recognize Mef2 consensus sequences (Figure 4A).
Forward (F) and Reverse (R) complementary DNA oligonucleo-
tides were designed based on a 30-basepair region of the Drosophila
melanogaster Actin 57B promoter which contains a centralized Mef2
DNA-binding site. We cloned three different variations of the
centralized core Mef2 sequence CTAWWWWTAG (Figure 4A).
Double-stranded oligonucleotide (ds-oligo) AT11 has the sequence
CTATTTTTAG, the wildtype sequence found in the Drosophila
Actin 57B promoter. Ds-oligo AT12 is the more commonly
observed Mef2 consensus, CTAAAAATAG, and is recognized by
human Mef2A and Mef2C proteins. The Mef2 consensus in ds-
oligo AT13 (CTATATATAG), was identified in the liverwort M.
polymorpha and is a perfect palindrome. Finally, as a negative
control, ds-oligo AT14 GTCACAAAA, does not contain a Mef2
binding consensus; it is replaced with the middle sporulation
element (MSE) that is recognized by the yeast Ndt80 protein, a
meiosis-specific transcriptional activator [59,60], and should not
be recognized by SmMef2.
The EMSA data produce 3 bands; the lower band is single-
stranded, biotin-labeled DNA and is consistent across all samples;
the mid-lower band is double-stranded labeled DNA; and the
upper band is DNA shifted due to protein binding by SmMef2.
We find that SmMef2 can bind to all three Mef2 consensus ds-
oligo sequences, AT11 (CTATTTTTAG, data not shown), AT12
(CTAAAAATAG), and AT13 (CTATATATAG); Figures 4B and
4C, Lanes 3). To address whether SmMef2 preferentially binds
either consensus sequence, we tested whether unlabeled ‘‘cold’’
AT11, AT12, or AT13 could compete for binding against labeled
probe AT12 or AT13. We initially predicted that SmMef2 would
most likely prefer the mammalian consensus, but under these
conditions, it preferred the consensus sequence from the liverwort
M. polymorpha, and followed by (in order of preference) AT12 and
AT11 (Figure 4B and 4C, Lanes 3–6). Ds-oligo AT14, the negative
control, did not compete against labeled probe for binding
(Figure 4B and 4C, Lanes 7). MBP protein alone was not able to
bind AT11 (not shown), AT12 or AT13 (Figure 4B and 4C, Lanes
2), demonstrating that SmMef2 was solely responsible for the shift.
These data, in combination with sequence conservation and the
ability for the SmMef2 to act as a TA, provide strong evidence that
SmMef2 encodes a Mef2 homolog. Therefore, we name this gene
SmMef2 for Schistosoma mansoni myocyte enhancer factor 2.
SmMef2 Developmental Expression
Mef2 proteins play significant roles in development, particularly
in early myogenesis and neurogenesis. We asked when SmMef2 is
expressed during schistosome development. To address this
question, we extracted RNA from sporocysts, cercariae, 4-hour
schistosomula, and adult worms and measured transcript levels by
quantitative PCR. There is little literature focused on myogenesis
or neurogenesis in schistosomes, although several electrophysio-
logical studies on muscle and nerve cells or physiological
descriptions have been published [69,70,71,72,73]. We made a
simple prediction that these developmental stages might undergo
myogenesis or neurogenesis for the following basic functions: 1)
Figure 5. SmMef2 Expression during development. Quantitative
PCR analysis of SmMef2 transcript profile during schistosome develop-
ment was performed using cyclophilin as a reference control.
doi:10.1371/journal.pntd.0001443.g005
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that must exit the molluscan and follow chemical and visual cues
to find and invade a mammalian host, 2) cercariae- for the reasons
just mentioned, 3) schistosomula- to produce new muscle and
neurons needed for motility, elongation, growth and development
into adult worms after transformation, and 4) adult worms- for
muscle motility, and muscle neuronal maintenance. There is some
discussion that myogenesis in newly transformed schistosomula
and adult worms might occur at the site of cercarial tail separation,
proposed due to the characterization of cercarial and adult
musculature patterns and the speculation that development of
adult musculature occurs directly from larval musculature or
undifferentiated stem cells derived from larvae [72]. This could
suggest that if Mef2 is involved in myogenesis, its expression
should be correlative with stages during which muscle develop-
ment occurs.
Quantitative PCR was used to generate an expression profile of
Mef2, with cyclophilin used as a reference gene and the sporocyst
stage used as a calibrator (Figure 5). Our data show a significant
enrichment of SmMef2 beginning at the schistosomula stage, with
decreased levels in the adult stage. The 6-fold increase in
expression from sporocysts to schistosomula is especially striking
given that levels drop 5-fold in cercariae; this means that Mef2
expression is upregulated over 30-fold during the transition from
cercariae to schistosomula. If SmMef2 is involved in myogenesis,
then this observation is consistent with the proposal by Mair et al
suggesting that the origins of myogenesis initiate after larval
transformation and continue in the adult worm [72], and this
increase correlates with significant changes in the organism’s
morphology and musculature during its transition to an adult.
Schistosomes Have Several Potential Mef2
Transcriptional Targets
Since schistosome parasites express Mef2, we asked whether we
could bioinformatically identify potential targets of SmMef2. We
screened for possible schistosome homologs of 56 genes regulated
by Mef2 in Drosophila [36] using a simple BLASTp analysis.
Twenty-six genes had either weak or strong Mef2 binding
sequences within 5,000 bp upstream from the predicted transla-
tion start site, while 8 of these genes contained the core Mef2
consensus sequence CTAWWWWTAG (Table 1). Three of these
genes (DNA replication licensing factor MCM7, actin, and four
Table 1. Putative targets of SmMef2.
Putative gene type (name) Smp number Binding site sequence Distance upstream Gene ID (NCBI)
actin* Smp_046590 cttttattaa 582 8349760
actin*# Smp_077850 CTATTTTTAG 3565 8345287
actin* Smp_161920 cttattatag, cttaatttag 2013, 3694 8349219
BMP antagonist noggin* Smp_099440 ctaattataa 31 8351146
crp1/csrp1/crip1*# Smp_087250 CTAAATATAG 1921 8355365
DNA replication licensing factor MCM7# Smp_032500 CTAAAAATAG 455 8348621
four and a half LIM domains* Smp_048560 ctataaataa, ctattaataa 2587, 4712 8341782
four and a half LIM domains*# Smp_143130 ctttattag, cttttattag, cttaaaatag, CTAAAAATAG 169, 2013, 4436, 4713 8351888
GLUT4 Smp_050640 ctaaaaataa, ctttttatag 230, 600 8343690
gsx family homeobox protein* Smp_138140 ctatttataa 1382 8347764
myosin XV Smp_127510 ctattattaa 1785 8353008
netrin# Smp_146840 CTAAATATAG, ctaatatta 1403, 4948 8348295
netrin Smp_151310 ctaatattag, ctaattttaa 1782, 2823 8340778
semaphorin 5-related# Smp_158550 CTAAATATAG 3459 8343948
TGF beta family* Smp_063190 cttaaaatag, ctatatttaa 310, 1172 8347411
tropomyosin# Smp_022170 CTAAATATAG 791 8343498
tropomyosin Smp_044010 ctttaattag, ctttttttag 1403, 4077 8350309
tropomyosin# Smp_085290 CTATTATTAG 1775 8347052
tubulin beta chain* Smp_078040 ctaaaaataa 4193 8353635
tubulin beta chain* Smp_079960 ctaaatttaa 1099 8347203
tubulin beta chain* Smp_079970 ctatttttaa, ctaaatttaa 1777, 2811 8347204
tubulin beta chain* Smp_035760 ctatttttaa 2832 8345905
tubulin delta chain Smp_154880 cttaatttag 3246 8342529
tubulin epsilon chain# Smp_028360 CTAATATTAG 948 8343061
WNT related*# Smp_167140 ctataaataa, CTAATAATAG, ctttatttag 456, 1387, 4817 8352146
WNT related*# Smp_152900 CTATAAATAG 433 8345780
KEY.
*:blasted from D. melanogaster gene with know Mef2 binding sites.
#: contains upstream sequence conforming to the strict Mef2 consensus.
Schistosome homologs of known Drosophila Mef2 transcriptional targets were individually screened for Mef2 binding sites within 5000 base pairs of the translation start
site. Genes were screened for strong consensus (capital letters, highlighted in grey: CTAWWWWTAG) and weak consensus sequences (lower case letters:
CTWWWWWTAG or CTAWWWWTAR). Upstream distances from the start codons are noted in base pairs.
doi:10.1371/journal.pntd.0001443.t001
Mef2 Transcriptional Activator in Schistosomes
www.plosntds.org 8 January 2012 | Volume 6 | Issue 1 | e1443and a half LIM domains) contain a sequence tested by our EMSA
analysis (Table 1). Sixteen genes are putatively involved in muscle
development, three in neuronal development, and one gene in
mini chromosome maintenance. Several proteins identified are
homologous to those in Drosophila. These include: three actin genes
homologous to Actin57B ; four tubulin beta chains homologous to
the beta tubulin gene 60D (Btub60D); BMP antagonist noggin and
Transforming Growth Factor beta (TGF-ß) family homologs to
Drosophila TGFß homolog Decapentaplegic (Dpp); two Wnt-
related proteins (Wnt proteins are involved in neurogenesis,
patterning and development) [74,75]; crp1/csrp1/crip1 and two,
four and a half LIM domains proteins with homology to Muscle
LIM protein at 60A (Mlp60A); and a Genomic Screened
Homeobox (Gsx) family homeobox protein with homology to
Mesenchyme homeobox 2 protein (Mox2), that is important for
early mesoderm patterning [76] and limb muscle development
[77] in mice, and which is correlative with SmMef2 being involved
in myogenesis in schistosome parasites. Each of these genes has a
Mef2 binding site, suggesting that they may be potential targets of
SmMef2.
Using quantitative PCR, we analyzed the transcriptional profile
of three genes (Netrin- Smp_146840, tropomyosin- Smp_022170,
and tubulin e-chain- Smp_028360) in sporocysts, cercariae, 4 h
schistosomula, and adults. Each of these genes has potential Mef2
binding sites located within 1500 base pairs upstream of the
translation start sites. Unfortunately, the initial results were
inconclusive, although expression level seemed to increase in
adults consistently (data not shown). One explanation for this
result may be that the Mef2 gene is transcribed, but Mef2 protein
has not yet activated its targets. This can be addressed by looking
at transcript levels of potential SmMef2 targets at later time points.
Conclusion
Here we show that schistosome parasites express a myocyte
enhancer factor 2, which we name SmMef2 for Schistosoma mansoni
myocyte enhancer factor 2. We identified SmMef2 in a search for
schistosome homologs to yeast transcriptional activators. SmMef2
has the conserved MADS box and Mef2 domains found in Mef2
activators. Mef2 proteins play a role in transcriptional activation.
Using the yeast 1-hybrid and EMSA, we show that SmMef2 is an
activator of transcription and that it specifically recognizes Mef2
consensus sequences in vitro. Furthermore, quantitative PCR data
show a developmentally regulated pattern of expression with
comparatively high transcript levels in four-hour schistosomula
and adult worms. This leads us to propose that SmMef2 may play
a significant role in the development from schistosomula to adult
worms. Finally, we describe potential targets of Mef2 genes that
are found in schistosomes and contain consensus sequences in
their promoter regions. Taken together, these data provide the first
description of a Mef2 activator in a helminth. Mef2 resides at an
early point in the evolution of animals. Understanding how
myogenesis works in schistosomes could provide insights into the
evolution of mammalian myogenesis. In addition, although we
know that the MADS box and Mef2 domains are highly
conserved, we observed that outside of this region, SmMef2 varies
in sequence dramatically from its mammalian and insect
homologs. This difference might provide an opportunity for its
exploitation as a potential drug target.
Supporting Information
Figure S1 Mef2 Sequence Analysis is seen. Sequence
analysis of SmMef2 (Smp_129430) against the yeast gene Rlm1 (A)
and human Mef2A (B). The conserved MADS-box (57 amino
acids) and the Mef2 domains (29 amino acids) are labeled.
(TIF)
Figure S2 SmMef2 DNA and Protein Sequences are
demonstrated. SmMef2 was cloned and sequenced. A G to A
transition at nucleotide is underlined, italicized and in bold. An **
is placed after nucleotide 1908 where the deletion of the 10
nucleotides AACAATAAT occurs. The coding sequences between
nucleotides 1595 and 1812, previously described as an intron,
encode for protein. These sequences are underlined.
(TIF)
Figure S3 Phylogenetic tree comparison of Mef2 homo-
logs using ClustalW. A phylogram phylogenetic tree was
drawn from a ClustalW-generated multiple sequence alignment of
Mef2 homologs using the neighbor-joining method (Gonnet
protein weight matrix, with the gap open set at 10, the gap
extension set at 0.2 and the gap distances set at 5).
(TIF)
Table S1 Gene names and DNA primer sequences used
for quantitative PCR analysis.
(DOC)
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